Atopic Dermatitis Market
Atopic Dermatitis Market Study by Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapies, PDE-4 Inhibitors, Antibiotics, Antihistamines, and Emollients from 2024 to 2034
Analysis of Atopic Dermatitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
- FACT4603MR
- 19 Mar 2024
- Healthcare
- 170 Pages
- 18 Tables
- 77 Figures
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecasts, by Drug Class
- 6.1. Corticosteroids
- 6.2. PDE4 Inhibitors
- 6.3. Biologics
- 6.4. Skin Barrier Emollients
- 6.5. CNI Immunosuppressants
- 6.6. Others
- 7. Global Market Analysis and Forecasts, by Distribution Channel
- 7.1. Hospital Pharmacies
- 7.2. Retail Pharmacies
- 7.3. Online Pharmacies
- 8. Global Market Analysis and Forecasts, by Region
- 8.1. North America
- 8.2. Europe
- 8.3. Asia Pacific
- 8.4. Latin America
- 8.5. Middle East & Africa
- 9. North America Market Analysis and Forecast
- 10. Europe Market Analysis and Forecast
- 11. Asia Pacific Market Analysis and Forecast
- 12. Latin America Market Analysis and Forecast
- 13. Middle East & Africa Market Analysis and Forecast
- 14. Competitive Landscape
- 14.1. Mylan N.V.
- 14.2. Pfizer, Inc.
- 14.3. LEO Pharma A/S
- 14.4. Teva Pharmaceutical Industries Ltd
- 14.5. Sanofi
- 14.6. Novartis AG
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2024 to 2034
Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2024 to 2034
Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
List Of Figures
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2024 and 2029
Figure 03: Global Market Value (US$ Mn) Forecast, 2024 to 2034
Figure 04: Global Market Value Share (%), by Drug Class (2024)
Figure 05: Global Market Value Share (%), by Distribution Channel (2024)
Figure 06: Global Market Value Share (%), by Region (2024)
Figure 07: Global Market Value Share Analysis, by Drug Class, 2024 and 2029
Figure 08: Global Market Attractiveness, by Drug Class, 2024 to 2029
Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2024 to 2034
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2024 to 2034
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2024 to 2034
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2024 to 2034
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2024 to 2034
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2024 to 2034
Figure 15: Global Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2024 to 2034
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2024 to 2034
Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2024 to 2034
Figure 19: Global Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 20: Global Market Value Share Analysis, by Region, 2024 and 2029
Figure 21: Global Market Attractiveness, by Region, 2024 to 2029
Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 23: North America Market Value Share (%), by Country, 2024 and 2029
Figure 24: North America Market Attractiveness, by Country, 2024 to 2029
Figure 25: North America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 26: North America Market Attractiveness, by Drug Class, 2024 to 2029
Figure 27: North America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 28: North America Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 32: Europe Market Value Share (%), by Drug Class, 2024 and 2029
Figure 33: Europe Market Attractiveness, by Drug Class, 2024 to 2029
Figure 34: Europe Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 35: Europe Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2024 and 2029
Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2024 to 2029
Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020 to 2027
Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2024 and 2029
Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 46: Latin America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 47: Latin America Market Attractiveness, by Drug Class, 2024 to 2029
Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2024 and 2034
Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2024 to 2034
Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2024 and 2034
Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2024 to 2034
Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2024 and 2034
Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2024 to 2034
Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2019 to 2023
Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2018 to 2020
Figure 59: Mylan N.V. Breakdown of Net Sales (%), by Region, 2020
Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2020
Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020
Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015 to 2020
Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2018 to 2020
Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)
Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)
Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2016 to 2020
Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2018 to 2020
Figure 68: Sanofi Revenue (US$ Bn), 2017 to 2020
Figure 69: Sanofi Regional Sales Breakdown (%), 2020
Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2020
Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2020
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2020
Figure 73: Novartis AG R&D Expenses (US$ Mn), 2018 to 2020
Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2016 to 2020
Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2018 to 2020
Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2020
Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2020
Atopic Dermatitis Market